Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Buclin

Showing results (51-60 of 107) with videos related to

Pageof 11
Sort By:
Kidney International. Supplement|June 1, 1996
Pharmacokinetic-pharmacodynamic relationships of three angiotensin II receptor antagonists in normal volunteersM Burnier, T Buclin, J Biollaz, et al.
Leukemia|April 13, 2007
Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levelsN Widmer, H Rumpold, G Untergasser, et al.
AIDS (London, England)|February 24, 2001
Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patientsC Marzolini, A Telenti, L A Decosterd, et al.
Schweizerische Medizinische Wochenschrift|December 26, 1992
[Acquired factor V inhibitor treated with intravenous immunoglobulins]T Buclin, P M Schmidt, J Hauert, et al.
Journal of Affective Disorders|July 14, 1999
Trace lithium in mood disordersM Dafflon, L A Décosterd, J Biollaz, et al.
Forensic Science International|December 1, 2001
Delta(9)-THC, 11-OH-Delta(9)-THC and Delta(9)-THCCOOH plasma or serum to whole blood concentrations distribution ratios in blood samples taken from living and dead peopleC Giroud, A Ménétrey, M Augsburger, et al.
Journal of Clinical Pharmacology|November 15, 2003
Pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically ill patientsC Robatel, L A Decosterd, J Biollaz, et al.
Journal of Cardiovascular Pharmacology|March 26, 1998
Effects of MDL 100,240, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase on the vasopressor response to exogenous angiotensin I and angiotensin II challenges in healthy volunteersP Rousso, T Buclin, J Nussberger, et al.
European Journal of Clinical Pharmacology|February 9, 2000
Bioavailability of repeated oral administration of MDL 100,240, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase in healthy volunteersP Rousso, T Buclin, J Nussberger, et al.
Der Nervenarzt|May 28, 2014
[Antiepileptics in women of childbearing age and during pregnancy: comparison of specialized information with the current state of knowledge in Germany and Switzerland]U Winterfeld, V Gotta, L E Rothuizen, et al.
Pageof 11

Showing results (51-60 of 107) with videos related to

Sort By:
Pageof 11
Kidney International. Supplement|June 1, 1996
Pharmacokinetic-pharmacodynamic relationships of three angiotensin II receptor antagonists in normal volunteersM Burnier, T Buclin, J Biollaz, et al.
Leukemia|April 13, 2007
Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levelsN Widmer, H Rumpold, G Untergasser, et al.
AIDS (London, England)|February 24, 2001
Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patientsC Marzolini, A Telenti, L A Decosterd, et al.
Schweizerische Medizinische Wochenschrift|December 26, 1992
[Acquired factor V inhibitor treated with intravenous immunoglobulins]T Buclin, P M Schmidt, J Hauert, et al.
Journal of Affective Disorders|July 14, 1999
Trace lithium in mood disordersM Dafflon, L A Décosterd, J Biollaz, et al.
Forensic Science International|December 1, 2001
Delta(9)-THC, 11-OH-Delta(9)-THC and Delta(9)-THCCOOH plasma or serum to whole blood concentrations distribution ratios in blood samples taken from living and dead peopleC Giroud, A Ménétrey, M Augsburger, et al.
Journal of Clinical Pharmacology|November 15, 2003
Pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically ill patientsC Robatel, L A Decosterd, J Biollaz, et al.
Journal of Cardiovascular Pharmacology|March 26, 1998
Effects of MDL 100,240, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase on the vasopressor response to exogenous angiotensin I and angiotensin II challenges in healthy volunteersP Rousso, T Buclin, J Nussberger, et al.
European Journal of Clinical Pharmacology|February 9, 2000
Bioavailability of repeated oral administration of MDL 100,240, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase in healthy volunteersP Rousso, T Buclin, J Nussberger, et al.
Der Nervenarzt|May 28, 2014
[Antiepileptics in women of childbearing age and during pregnancy: comparison of specialized information with the current state of knowledge in Germany and Switzerland]U Winterfeld, V Gotta, L E Rothuizen, et al.
Pageof 11